Member Info for thevid

Dvrg also have a MoU with Abingdon Health for lateral flow tests. All just a side show now, but who knows.

From March 2022.

Just to clarify, i emailed this question to DVRG and was told by GB they are working with both companies. They can be used as binding agents on the MicrotoxPD chips that capture the dangerous pathogens, such as SARS-CoV-2 and many other biomarkers.

We work with both companies.

@bella
I had email reply on this question and was told still working with both companies.

I must say he does repeatedly say it. Over and over again, he is funny though.

Lol. well done big.

You would need a crowbar to get these off me now.

One day you might be right big, law of averages and all that.

I bet the long winter nights just fly bye in your house super.

Time will tell super, you`re starting to get boring mate.

Thanks for taking the time Gerry.

Don`t know if posted before but interesting read.

https://www.fda.gov/drugs/news-events-human-drugs/generic-drug-approval-process

Been having a read up on FDA web site and it seems AML should qualify for Breakthrough therapy designation or one of the other fast track routes going by their criteria in m/o.
for AML hemo car-t, an acute form of leukemia for which there is currently no effective treatment."
Also something called a Material threat medical countermeasure priority review, Medical countermeasures or MCMs, seems to fit CBR like a glove when it`s ready.

https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies

Agreed strong buy, but will not be t/o

Taken from pubmed
Abstract

The maximum tolerated dose (MTD) has been the classically recommended phase II dose for cytotoxic chemotherapy anticancer agents. However, the development of molecular targeted therapies with highly specific mechanisms of action has raised questions about the paradigm of dosing at the MTD. Inhibition of the molecular target may occur at dose levels substantially below those producing dose limiting toxicities. The impact of targeted therapies on our dose selection strategies has been immense; however, defining the MTD in phase I oncology trials still provides valuable information for future drug development. But, the MTD should not be selected blindly as the recommended phase II dose for efficacy testing. Optimal dose selection for targeted cancer agents needs to be evaluated using all available information collected during the early stages of drug development. Definition of the optimal dose may need to be deferred until randomized phase II trials can be conducted. Future clinical trail designs in oncology drug development need to reflect this paradigm shift.

lol, fair enough.

@jhfh Do you think it could well be Eli involved with CBR ?

Is Hurst a bot or what ?

lol

"couldn't quite be sure from the vid that a raise will not be needed."
I can assure you i have no idea if raise will be needed. :)